IL-36 Receptor Antagonist with Special Emphasis on IL-38. (January 2013)

• Record Type: Journal Article
• Authors: Shaik, Y.; Sabatino, G.; Maccauro, G.; Varvara, G.; Murmura, G.; Saggini, A.; Rosati, M.; Conti, F.; Cianchetti, E.; Caraffa, A.; Antinolfi, P.; Pandolfi, F.; Potalivo, G.; Galzio, R.; Conti, P.; Theoharides, T.C.
• Is Part Of: International journal of immunopathology and pharmacology. Volume 26:Number 1(2013)
• Page Start: 27
• Page End: 36
• Publication Date: 2013-01
• Subjects: IL-36 -- IL-38 -- cytokines -- inflammation -- immunity; Immunopathology -- Periodicals; Pharmacology -- Periodicals; Inflammation -- Periodicals; 615.1
• DOI: 10.1177/039463201302600103
• Languages: English
• ISSNs: 0394-6320

Abstract

IL-36 is another family member of IL-1 and induces the production of proinflammatory cytokines and activates MAPK and NFκB pathways. IL-36 is a common mediator of innate and adaptive immune response and is inhibited by IL-36 receptor antagonist (RA). IL-36RA acts on IL-36 receptor ligand which exerts proinflammatory effect in vivo and in vitro . IL-38 binds to IL-36 receptor as does IL-36RA and has similar biological effects on immune cells. IL-38 is also a member of IL-1 cytokine and shares some characteristics of IL-1RA, binding the same IL-1 receptor type I. IL-38 plays a role in the pathogenesis of inflammatory diseases, exerting protective effect in some autoimmune diseases. Both IL-38 and IL-36RA have an anti-inflammatory biological effect, however in some cases have contrary effects.